title: Kaletra approved in Canada.
abstract: On March 9, 2001, Health Canada granted permission to Abbott Laboratories for the sale of Kaletra (a combination of protease inhibitors lopinavir and ritonavir), formerly known as ABT-378/r, for the treatment of HIV infection in adults and children six months or older. Kaletra was approved for sale in the U.S. in September 2000.
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002170:Canada; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006297:Health Services Accessibility; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir